Data Shows Majority of US Users Discontinue 'Miracle' Weight-loss Drugs

Friday, 12 July 2024, 08:15

The use of weight-loss drugs like Ozempic and Zepbound is facing scrutiny, as President Biden raises concerns over their cost. Recent data reveals that a significant percentage of users in the US stop taking these medications within two years, showcasing challenges in long-term adherence. Despite their 'miracle' label, the sustainability of these drugs for obesity management is under question.
South China Morning Post
Data Shows Majority of US Users Discontinue 'Miracle' Weight-loss Drugs

Weight-loss Drugs Facing Scrutiny

The high cost of weight-loss drugs like Ozempic and Zepbound has drawn criticism from President Biden.

User Discontinuation Rates

Data indicates that a majority of users in the US stop taking these 'miracle' medications within two years.

Challenges in Long-term Adherence

Questions arise regarding the sustainability and effectiveness of these drugs for managing obesity.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe